Document Detail

A novel transport and delivery mechanism underpins the effectiveness of prolyl-m-sarcolysyl-p-fluorophenylalanine (PSF) in a human melanoma xenograft nude-mouse model.
MedLine Citation:
PMID:  18627526     Owner:  NLM     Status:  MEDLINE    
The alkylating peptide PSF shows very promising results in vitro on different cancer cells but its efficacy in animals has not been assessed. Here we evaluate the efficacy of PSF in human melanoma-bearing nude mice and examine the underlying mechanism. In melanoma-bearing nude mice, escalating doses of PSF showed dose-dependent responses and reached tumor regression with an optimal dose of 20 mg/kg for 1 month. A comparison of PSF with its free moiety m-sarcolysin and melphalan showed a highly significant advantage of PSF. Furthermore, dose fractionation yielded an even better control of tumor regrowth. In vitro studies unraveled an original delivery mechanism based on the rapid binding of PSF mainly due to red blood cells to form a pro-drug complex and the subsequent release of active metabolites by tumor-associated proteolytic enzymes. Blood kinetics showed one major metabolite partially released over time, while in the presence of melanoma cells three additional metabolites are generated. Interestingly, tumor-shed proteases also induce the production of these metabolites and varying combinations of enzyme inhibitors indicate the involvement of metallo- and other families of proteases in the delivery process. This particular transport and delivery of such an alkylating agent may have several benefits, mainly lowering the drug-free moiety in plasma and at the same time increasing its concentration in protease rich areas such as tumors.
Karen M E Dierickx; Renato Morandini; Thi Hien Nguyen; François Salès; Jean-Michel Kauffmann; Ghanem E Ghanem
Related Documents :
1738186 - Microculture-based chemosensitivity testing: a feasibility study comparing freshly expl...
2419816 - Neovascular glaucoma after helium ion irradiation for uveal melanoma.
20557286 - Electroporation gene therapy preclinical and clinical trials for melanoma.
17611626 - Comprehensive expression profiling of tumor cell lines identifies molecular signatures ...
10967466 - Antitumor activity of methanolic extract of cassia fistula l. seed against ehrlich asci...
9181056 - Polyomavirus-induced malignant transformation: comparative analysis of wild type and mu...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-06-20
Journal Detail:
Title:  Pigment cell & melanoma research     Volume:  21     ISSN:  1755-1471     ISO Abbreviation:  Pigment Cell Melanoma Res     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-08-19     Completed Date:  2008-10-20     Revised Date:  2009-12-11    
Medline Journal Info:
Nlm Unique ID:  101318927     Medline TA:  Pigment Cell Melanoma Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  439-50     Citation Subset:  IM    
Laboratory of Oncology and Experimental Surgery, Institut J Bordet, Université libre de Bruxelles, Belgium.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  pharmacokinetics,  pharmacology
Dipeptides / administration & dosage*,  pharmacokinetics,  pharmacology
Drug Delivery Systems / methods*
Drug Stability
Melanoma / drug therapy*,  pathology
Melphalan / pharmacology,  therapeutic use
Mice, Nude
Models, Biological
Treatment Outcome
Tumor Cells, Cultured
Xenograft Model Antitumor Assays
p-Fluorophenylalanine / administration & dosage,  analogs & derivatives*,  pharmacokinetics,  pharmacology
Reg. No./Substance:
0/Antineoplastic Agents; 0/Dipeptides; 148-82-3/Melphalan; 38305-84-9/propyl-3-sarcolysin-4-fluorophenylalanine; 60-17-3/p-Fluorophenylalanine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Neutrophil infiltration in normal human skin after exposure to different ultraviolet radiation sourc...
Next Document:  Pigmentation effects of solar-simulated radiation as compared with UVA and UVB radiation.